Vimta Labs Limited has informed stock exchanges that its Board of Directors, at their meeting held on May 6, 2026, has recommended the re-appointment of Dr. S. P. Vasireddi (DIN: 00242288) as Executive Chairman of the company. The recommendation was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was based on the recommendations of the Nomination and Remuneration Committee and the approval of the Audit Committee.

Re-appointment Details

The proposed re-appointment is subject to the approval of shareholders at the ensuing Annual General Meeting. The key details of the re-appointment are outlined below:

As Dr. S. P. Vasireddi has attained the age of 77 years, his re-appointment and continuation as Executive Chairman is subject to approval of the members of the company by way of a special resolution at the ensuing Annual General Meeting, as per the provisions of Section 196(3)(a) of the Companies Act, 2013. He is also liable to retire by rotation.

Profile and Experience

Dr. S. P. Vasireddi is the founder of Vimta Labs and has been associated with the company since its inception, playing a pivotal role in its growth and development over the past four decades. His tenure with the company has spanned several key roles:

• Served as Chairman & Managing Director until July 13, 2013
• Served as Executive Chairman up to June 30, 2018
• Served as Non-Executive Chairman from July 1, 2018 to June 30, 2023
• Resumed the position of Executive Chairman following the above tenure

Dr. Vasireddi brings over four decades of industry experience, with expertise in strategic leadership, business development, and corporate governance, contributing to the company's sustained growth and long-term objectives. He has also been instrumental in setting up a centre of excellence — the VIMTA-UNIDO South Cooperation Training Centre.

Advisory and Governing Board Associations

Given his extensive knowledge and experience, Dr. Vasireddi has been nominated as a member on the Advisory/Governing Boards of several apex scientific bodies. His present/past associations include:

• Member of Central Advisory Committee – Food Safety & Standards Authority of India (FSSAI)
• Member of the Governing Board of NABL
• Chairperson – NABL, Risk Management Committee

Additional Disclosures

The following additional disclosures have been made in accordance with regulatory requirements:

The intimation was filed by Sujani Vasireddi, Company Secretary and Compliance Officer of Vimta Labs, in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Vimta Labs Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The company reported total income of ₹4,163 Mn for FY26, up 19.5% year-on-year from ₹3,482 Mn, driven by strong growth in revenue from operations. For Q4 FY26, total income rose 16.6% YoY to ₹1,120 Mn, reflecting sustained business momentum across the year. The Managing Director attributed the performance to the exceptional execution of the Pharma and Food divisions.

Financial Performance Overview

The company's revenue from operations for FY26 reached ₹4,073 Mn, compared to ₹3,440 Mn in the prior year. On a quarterly basis, Q4 FY26 revenue from operations stood at ₹1,092 Mn. The following table presents a detailed breakdown of the company's financial performance:

Share and Market Information

As of March 31, 2026, Vimta Labs had a market capitalisation of INR 1,701.01 Cr, with a free-float of 64.15% translating to a free-float market cap of INR 1,091.20 Cr. The company maintained a lean balance sheet with total debt of ₹33.3 Mn and cash and cash equivalents of ₹650.6 Mn. The total shares outstanding stood at 4,46,69,355, with a three-month average daily trading volume of 2,42,931.67 shares (INR 11.39 Cr).

Board Decisions and Corporate Actions

The Board of Directors recommended a dividend of ₹2/- (Rupee Two only) per equity share of face value ₹2/- each for FY26, subject to shareholders' approval at the ensuing Annual General Meeting. The record date for the payment of dividend is fixed as June 18, 2026, and the dividend will be paid on or before July 8, 2026. The Board also approved the notice for the 36th Annual General Meeting, scheduled for Thursday, June 25, 2026.

Additionally, the Board recommended the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a term of five years effective July 1, 2026, to June 30, 2031, subject to shareholder approval. Dr. S. P. Vasireddi, the Founder of the company, has over four decades of experience and holds 51,97,050 equity shares. The Board also approved a proposal for the incorporation of a wholly owned subsidiary in the USA.